Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold

Around a third of non-small cell lung cancer (NSCLC) patients present with stage III disease. The majority are not suitable for surgery and until very recently, the standard-of-care for unresectable, good performance status patients with stage III disease has been platinum-doublet chemotherapy with high dose radiotherapy (RT), with no additional treatment.